Q1 2024 Holdings
Filed 2024-05-15 | 57 holdings | $1.2B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Sarepta Therapeutics Inc(SRPT)Call | COM | 803607100 | $155.4M | 1,200,000 | 12.6% |
| Alnylam Pharmaceuticals Inc(ALNY)Call | COM | 02043Q107 | $74.7M | 500,000 | 6.0% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $65.8M | 1,500,000 | 5.3% |
| Immunocore Hldgs PLC(IMCR) | ADS | 45258D105 | $58.5M | 900,000 | 4.7% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $57.4M | 1,775,000 | 4.6% |
| Ocular Therapeutix Inc(OCUL) | COM | 67576A100 | $52.0M | 5,811,436 | 4.2% |
| Sarepta Therapeutics Inc(SRPT) | COM | 803607100 | $51.8M | 400,000 | 4.2% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $49.6M | 4,383,875 | 4.0% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $49.1M | 1,730,000 | 4.0% |
| Apellis Pharmaceuticals Inc(APLS) | COM | 03753U106 | $47.0M | 800,000 | 3.8% |
| Rocket Pharmaceuticals Inc(RCKT) | COM | 77313F106 | $35.0M | 1,300,000 | 2.8% |
| Silence Therapeutics PLC(SLN) | ADS | 82686Q101 | $31.1M | 1,476,061 | 2.5% |
| Structure Therapeutics Inc(GPCR) | SPONSORED ADS | 86366E106 | $30.9M | 720,058 | 2.5% |
| Geron Corp(GERN) | COM | 374163103 | $29.7M | 9,000,000 | 2.4% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $27.3M | 650,000 | 2.2% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $26.4M | 1,574,220 | 2.1% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $24.8M | 575,000 | 2.0% |
| Annexon Inc(ANNX) | COM | 03589W102 | $21.9M | 3,050,000 | 1.8% |
| Adverum Biotechnologies Inc(AVU0) | COM NEW | 00773U207 | $21.2M | 1,499,999 | 1.7% |
| Design Therapeutics Inc(DSGN) | COM | 25056L103 | $20.3M | 5,032,501 | 1.6% |
| Akero Therapeutics Inc(AKRO) | COM | 00973Y108 | $20.2M | 800,000 | 1.6% |
| Structure Therapeutics Inc(GPCR)Call | SPONSORED ADS | 86366E106 | $19.3M | 450,000 | 1.6% |
| Astria Therapeutics Inc(CATBUSD) | COM | 04635X102 | $17.5M | 1,244,960 | 1.4% |
| Cybin Inc(CYBNEUR) | COM | 23256X100 | $16.5M | 40,000,000 | 1.3% |
| Xencor Inc(XNCR) | COM | 98401F105 | $14.4M | 650,000 | 1.2% |
| Astria Therapeutics Inc(CATBUSD)Call | COM | 04635X102 | $14.1M | 1,000,000 | 1.1% |
| CG Oncology Inc(CGON) | COM | 156944100 | $13.2M | 300,000 | 1.1% |
| Engene Holdings Inc(ENGN) | COM | 29286M105 | $12.9M | 800,000 | 1.0% |
| Kyverna Therapeutics Inc(KYTX) | COM | 501976104 | $12.4M | 500,000 | 1.0% |
| Viridian Therapeutics Inc(VRDN) | COM | 92790C104 | $12.3M | 700,000 | 1.0% |
| Cullinan Oncology Inc(CGEM) | COM | 230031106 | $11.9M | 700,000 | 1.0% |
| Immatics N.v(IMTX) | SHS | N44445109 | $10.5M | 1,000,000 | 0.9% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $9.5M | 250,000 | 0.8% |
| Fulcrum Therapeutics Inc(FULC)Call | COM | 359616109 | $9.4M | 1,000,000 | 0.8% |
| Lineage Cell Therapeutics in(LCTX) | COM | 53566P109 | $9.3M | 6,250,000 | 0.7% |
| Praxis Precision Medicines I(PRAX) | COM NEW | 74006W207 | $9.2M | 150,000 | 0.7% |
| Applied Therapeutics Inc(APLT) | COM | 03828A101 | $9.0M | 1,350,000 | 0.7% |
| Syndax Pharmaceuticals Inc(SNDX) | COM | 87164F105 | $8.3M | 350,000 | 0.7% |
| Trevi Therapeutics Inc(TRVI) | COM | 89532M101 | $7.6M | 2,200,000 | 0.6% |
| Annexon Inc(ANNX)Call | COM | 03589W102 | $7.2M | 1,000,000 | 0.6% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $7.0M | 100,000 | 0.6% |
| Kura Oncology Inc(KURA) | COM | 50127T109 | $6.4M | 300,000 | 0.5% |
| Neumora Therapeutics Inc.(NMRA) | COM | 640979100 | $6.2M | 382,345 | 0.5% |
| Atyr Pharma Inc(ATYR) | COM NEW | 002120202 | $6.0M | 3,100,000 | 0.5% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $5.6M | 150,000 | 0.5% |
| Larimar Therapeutics Inc(LRMR)Call | COM | 517125100 | $5.3M | 700,000 | 0.4% |
| Elevation Oncology Inc | COM | 28623U101 | $5.1M | 1,000,000 | 0.4% |
| Nextcure Inc | COM | 65343E108 | $4.3M | 1,925,000 | 0.3% |
| Allakos Inc(ALLKGUSD) | COM | 01671P100 | $3.7M | 2,900,000 | 0.3% |
| Unicycive Therapeutics Inc | COM | 90466Y103 | $3.0M | 3,469,927 | 0.2% |